Home  »  Industry   »  Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) Underv...

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) Undervalued? Fundamentals Hard To Beat?

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) Relative Strength Index (RSI) is 64.84, with weekly volatility at 3.57% and ATR at 0.37. The IRWD stock’s 52-week price range has touched low of $8.63 and a $12.55 high. Intraday shares traded counted 2.04 million, which was 5.52% higher than its 30-day average trading volume of 2.16M. Its shares traded higher over the last trading session, gaining 1.74% on 05/14/21. The shares fell to a low of $11.50 before closing at $11.68. IRWD’s previous close was $11.48 while the outstanding shares total 160.97M. The firm has a beta of 1.35, a 12-month trailing P/E ratio of 13.20.

Investors have identified the Drug Manufacturers – Specialty & Generic company Ironwood Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.86 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

Ironwood Pharmaceuticals Inc. (IRWD) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 538.25 million total, with 23.6 million as their total liabilities.

Having a look at the company’s valuation, the company is expected to record 1.18 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on IRWD sounds very interesting.

Is the stock of IRWD attractive?

In related news, Director, DENNER ALEXANDER J bought 75,000 shares of the company’s stock in a transaction that recorded on Mar 10. The purchase was performed at an average price of 10.54, for a total value of 790,500. As the purchase deal closes, the Director, DENNER ALEXANDER J now bought 150,000 shares of the company’s stock, valued at 1,545,000. Also, Director, DENNER ALEXANDER J bought 175,000 shares of the company’s stock in a deal that was recorded on Mar 05. The shares were cost at an average price of 10.01 per share, with a total market value of 1,751,750. Following this completion of disposal, the Director, DENNER ALEXANDER J now holds 250,000 shares of the company’s stock, valued at 2,500,000. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.70%.

1 out of 5 analysts covering the stock have rated it a Buy, while 4 have maintained a Hold recommendation on Ironwood Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the IRWD stock. The 12-month mean consensus price target for the company’s shares has been set at $12.33.

Leave a Comment

Your email address will not be published. Required fields are marked *